GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...

The Justice Department is trying to distance itself from Miller and his expectations for federal agents to arrest 3,000 ...

The president of the United States of America on Monday weighed in on the viral American Eagle advertisement featuring Sydney ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Investing.com - Barclays handhaaft zijn Equalweight-advies en koersdoel van DKK 375,00 voor Novo Nordisk (CSE:NOVOB) (NYSE:NVO) na berichten over een gepland Medicare-pilotprogramma voor GLP-1-medicij ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...